Program
bemnifosbuvir
Also written as “AT-527”, “Bemnifosbuvir (BEM)” and “AT-527 + digoxin”.
Its studies are mostly in Hepatitis C, Chronic · COVID-19 · Renal Insufficiency, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Atea Pharmaceuticals | 240 open or running | phase 3since Nov 26, 2022 | Jul 13, 2017 | none ahead |
| Hoffmann-La Roche | 20 open or running | phase 3since May 10, 2021 | Jan 12, 2021 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 11 studies since Jul 13, 2017.
- Oct 28, 2021Phase 1 study in Healthy Volunteers StudyAtea Pharmaceuticals · NCT05137626 · 29 enrolled · Canada
- Nov 16, 2021Phase 1 study in Healthy Volunteer StudyAtea Pharmaceuticals · NCT05154123 · 29 enrolled · Canada
- Feb 16, 2022Phase 1 study in Healthy Volunteer StudyAtea Pharmaceuticals · NCT05256732 · 136 enrolled · Canada
- Oct 26, 2022Phase 1 study in Renal InsufficiencyAtea Pharmaceuticals · NCT05618314 · 36 enrolled · Canada
- Nov 26, 2022Phase 3 study in COVID-19Atea Pharmaceuticals · NCT05629962 · 2,285 enrolled · United States, Argentina, Brazil and more
- Jan 24, 2023Phase 1 study in Healthy VolunteerAtea Pharmaceuticals · NCT05724693 · 39 enrolled · United States
- Feb 9, 2023Phase 1 study in Healthy Volunteer StudyAtea Pharmaceuticals · NCT05731843 · 32 enrolled · Canada
- Apr 20, 20232 phase 1 studies in Healthy Volunteer StudyAtea Pharmaceuticals · NCT05905497, NCT05905484
- Jun 6, 2023Phase 2 study in Hepatitis C, ChronicAtea Pharmaceuticals · NCT05904470 · 275 enrolled · United States, Brazil, Canada and more
- Jan 2, 2024Phase 1 study in Healthy Volunteer StudyAtea Pharmaceuticals · NCT06204679 · 42 enrolled · United States
- Mar 24, 2025Phase 1 study in Renal InsufficiencyAtea Pharmaceuticals · NCT06911320 · 28 enrolled · United States
- May 19, 2025Phase 1 study in Healthy Volunteer StudyAtea Pharmaceuticals · NCT07007806 · 20 enrolled · United States
- Nov 19, 2025Phase 1 study in Healthy Volunteer StudyAtea Pharmaceuticals · NCT07272889 · 24 enrolled · Canada
- Dec 18, 2025Phase 1 study in Healthy Volunteer StudyAtea Pharmaceuticals · NCT07314346 · 30 enrolled · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 26 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07314346Healthy Volunteer Study · United States | 1 | Completed | Atea Pharmaceuticals | Jul 23, 2026 | 30 |
| NCT07272889Healthy Volunteer Study · Canada | 1 | Completed | Atea Pharmaceuticals | Feb 17, 2026 | 24 |
| NCT07007806Healthy Volunteer Study · United States | 1 | Completed | Atea Pharmaceuticals | Jun 28, 2025 | 20 |
| NCT06911320Renal Insufficiency · United States | 1 | Completed | Atea Pharmaceuticals | Apr 30, 2026 | 28 |
| NCT06204679Healthy Volunteer Study · United States | 1 | Completed | Atea Pharmaceuticals | Aug 25, 2024 | 42 |
| NCT05904470Hepatitis C, Chronic · United States, Brazil, Canada and more | 2 | Completed | Atea Pharmaceuticals | Dec 9, 2024 | 275 |
| NCT05905497Healthy Volunteer Study · United States | 1 | Completed | Atea Pharmaceuticals | May 19, 2023 | 14 |
| NCT05905484Healthy Volunteer Study · Canada | 1 | Completed | Atea Pharmaceuticals | May 31, 2023 | 35 |
| NCT05731843Healthy Volunteer Study · Canada | 1 | Completed | Atea Pharmaceuticals | Mar 15, 2023 | 32 |
| NCT05724693Healthy Volunteer · United States | 1 | Completed | Atea Pharmaceuticals | Apr 23, 2024 | 39 |
| NCT05629962COVID-19 · United States, Argentina, Brazil and more | 3 | Completed | Atea Pharmaceuticals | Apr 25, 2024 | 2,285 |
| NCT05618314Renal Insufficiency · Canada | 1 | Completed | Atea Pharmaceuticals | Jun 15, 2024 | 36 |
| NCT05256732Healthy Volunteer Study · Canada | 1 | Completed | Atea Pharmaceuticals | Aug 23, 2022 | 136 |
| NCT05154123Healthy Volunteer Study · Canada | 1 | Completed | Atea Pharmaceuticals | Dec 23, 2021 | 29 |
| NCT05137626Healthy Volunteers Study · Canada | 1 | Completed | Atea Pharmaceuticals | Dec 12, 2021 | 29 |
| NCT05004415Healthy Volunteer Study · United States | 1 | Completed | Atea Pharmaceuticals | Aug 12, 2021 | 6 |
| NCT04889040COVID-19 · Argentina, Belgium, Brazil and more | 3 | Terminated | Hoffmann-La Roche | Dec 2, 2021 | 216 |
| NCT04877769Healthy Volunteer Study · United Kingdom | 1 | Completed | Atea Pharmaceuticals | Aug 31, 2021 | 24 |
| NCT04865445Healthy Volunteer Study · Canada | 1 | Completed | Atea Pharmaceuticals | May 15, 2021 | 24 |
| NCT04784000Healthy Volunteer Study · Canada | 1 | Completed | Atea Pharmaceuticals | Apr 10, 2021 | 20 |
| NCT04711187Healthy Volunteer Study · Canada | 1 | Completed | Atea Pharmaceuticals | Sep 15, 2021 | 81 |
| NCT04709835COVID-19 · Canada, Greece, Ireland and more | 2 | Completed | Hoffmann-La Roche | Sep 17, 2021 | 104 |
| NCT04396106COVID-19 · United States, Argentina, Belgium and more | 2 | Terminated | Atea Pharmaceuticals | Jan 10, 2022 | 83 |
| NCT04309734Hepatitis C · Belgium | 2 | Withdrawn | Atea Pharmaceuticals | Jun 2022 | 0 |
| NCT04019717Hepatitis C · Belgium, Mauritius, Moldova, Republic of | 2 | Completed | Atea Pharmaceuticals | Jan 29, 2020 | 10 |
| NCT03219957Hepatitis C, Chronic · Belgium, Moldova, Republic of | 1 | Completed | Atea Pharmaceuticals | Jun 20, 2018 | 88 |
How it is read
Names in the registry
- “AT-527”, 10 entries
- “Bemnifosbuvir (BEM)”, 4 entries
- “AT-527 + digoxin”, 2 entries
- “AT-527 550 mg + midazolam”, 2 entries
- “Buprenorphine/Naloxone + BEM/RZR”, 1 entry
Conditions, from the studies’ own filings
- Hepatitis C, Chronic, 4 studies
- COVID-19, 4 studies
- Renal Insufficiency, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.